TransCelerate to Transform Clinical Research at PHUSE US Connect 2026

TransCelerate BioPharma, a prominent nonprofit organization dedicated to enhancing global health through improved clinical research, is preparing to take center stage at the upcoming PHUSE US Connect conference 2026. Scheduled from March 22 to March 26 in Austin, Texas, this event will bring together experts and innovators from the clinical data science community to discuss pivotal topics such as patient-centered innovation, artificial intelligence (AI), and real-world evidence.

With a strong commitment to fostering cross-industry collaboration, TransCelerate aims to offer practical solutions that both accelerate and simplify the clinical research process while prioritizing patient safety. The organization’s participation in this notable conference underscores its vital role in shaping conversations around clinical advancements and enhancing the framework within which clinical trials operate.

Two key figures from TransCelerate will deliver keynote speeches during the event. Lilliam Rosario, Ph.D., serving as Program Director, and Rob DiCicco, Vice President of Portfolio Management, will both emphasize the significant impact of AI, real-world data, and collaborative efforts across the pharmaceutical industry in transforming clinical development practices.

Dr. Rosario's keynote, titled "Patients First Collaboration and Innovation Shaping the Future of Safe and Effective Medicines," will be presented on March 26 at 9:00 a.m. CT. She will draw from her extensive experience leading initiatives at the FDA's Office of Computational Science to discuss the importance of shared data standards and structured workflows. The aim is to highlight how enhanced collaboration throughout the drug development lifecycle can minimize uncertainty, bolster regulatory confidence, and lead to safer, patient-focused development outcomes. Dr. Rosario stated, "Translational safety particularly hinges on our effectiveness in aligning data, standards, and collaboration across the industry," emphasizing that PHUSE provides a timely platform for advancing these crucial discussions.

On March 25 at 9:00 a.m. CT, Mr. DiCicco will present his keynote, "Modernizing the Clinical Trials Enterprise: Evidence Generation in the Next 10 Years," in the Real-World Evidence Pavilion. His presentation will tackle the unfulfilled promise of the Twenty-First Century Cures Act, which aimed to utilize electronic health data more effectively, and will showcase how innovation across technology and industry partnerships can help realize this goal.

Beyond their keynote addresses, Dr. Rosario and Mr. DiCicco will participate in several panel discussions. One such discussion on March 23 at 4:00 p.m. CT will be titled "From Knowledge to Harnessing Insight: Rethinking Learning, Systems, and Growth through Personal Knowledge Management." This conversation aims to inspire organizations to transcend conventional knowledge management approaches, fostering adaptive learning cultures that convert information into actionable insights.

Additionally, at 4:00 p.m. CT on March 25, Dr. Rosario will engage in the panel "Lead the AI Era – Act Now, Transform Pharma From Data to Breakthroughs," discussing the vital need to scale AI transformations responsibly while maintaining an equilibrium between governance and innovation in pharmaceutical development. Mr. DiCicco will also take part in a session discussing the integration of AI, digital health, and patient-centered real-world evidence at 9:45 a.m. CT that same day, exploring how these technologies can advance evidence strategies within healthcare systems.

For those interested in meeting TransCelerate's leadership during the PHUSE US Connect event, they can contact Hannah Davis at [email protected] to arrange a meeting. This engagement will provide a unique opportunity to explore the organization’s initiatives and how they continue to influence the dialogue surrounding clinical trial efficiency and patient-centric practices.

About TransCelerate BioPharma Inc.

TransCelerate BioPharma is a nonprofit organization committed to fostering collaboration within the global biopharmaceutical research and development community. With its headquarters near Philadelphia, TransCelerate encompasses 18 member companies and boasts a dynamic portfolio aimed at revolutionizing connectivity in clinical trials, promoting information sharing, and facilitating innovative study designs. Further information about TransCelerate can be accessed through their website.